EP2363143A3 - MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene - Google Patents

MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene Download PDF

Info

Publication number
EP2363143A3
EP2363143A3 EP10012380A EP10012380A EP2363143A3 EP 2363143 A3 EP2363143 A3 EP 2363143A3 EP 10012380 A EP10012380 A EP 10012380A EP 10012380 A EP10012380 A EP 10012380A EP 2363143 A3 EP2363143 A3 EP 2363143A3
Authority
EP
European Patent Office
Prior art keywords
gag
pol genes
hiv envelope
modified hiv
expressing modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10012380A
Other languages
English (en)
French (fr)
Other versions
EP2363143A2 (de
Inventor
Bernard Moss
Patricia L. Earl
Linda Wyatt
Leigh Anne Eller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
US Department of Health and Human Services
United States Department of the Army
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
US Department of Health and Human Services
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc, US Department of Health and Human Services, United States Department of the Army filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of EP2363143A2 publication Critical patent/EP2363143A2/de
Publication of EP2363143A3 publication Critical patent/EP2363143A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP10012380A 2003-03-28 2004-03-29 MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene Withdrawn EP2363143A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45917503P 2003-03-28 2003-03-28
EP04758588A EP1610816B1 (de) 2003-03-28 2004-03-29 Mva virus, der modifizierte hiv hülle, gag und pol gene exprimiert

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP04758588.0 Division 2004-03-29

Publications (2)

Publication Number Publication Date
EP2363143A2 EP2363143A2 (de) 2011-09-07
EP2363143A3 true EP2363143A3 (de) 2012-02-15

Family

ID=33131868

Family Applications (4)

Application Number Title Priority Date Filing Date
EP10012380A Withdrawn EP2363143A3 (de) 2003-03-28 2004-03-29 MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene
EP10012381A Withdrawn EP2371380A1 (de) 2003-03-28 2004-03-29 MVA Virus, der modifizierte HIV hülle, gag und pol gene exprimiert
EP04758588A Expired - Lifetime EP1610816B1 (de) 2003-03-28 2004-03-29 Mva virus, der modifizierte hiv hülle, gag und pol gene exprimiert
EP10012379A Withdrawn EP2359851A3 (de) 2003-03-28 2004-03-29 MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP10012381A Withdrawn EP2371380A1 (de) 2003-03-28 2004-03-29 MVA Virus, der modifizierte HIV hülle, gag und pol gene exprimiert
EP04758588A Expired - Lifetime EP1610816B1 (de) 2003-03-28 2004-03-29 Mva virus, der modifizierte hiv hülle, gag und pol gene exprimiert
EP10012379A Withdrawn EP2359851A3 (de) 2003-03-28 2004-03-29 MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene

Country Status (5)

Country Link
US (2) US7303754B2 (de)
EP (4) EP2363143A3 (de)
AU (1) AU2004226345B2 (de)
CA (1) CA2520637A1 (de)
WO (1) WO2004087201A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2363143A3 (de) * 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene
US9453239B2 (en) * 2004-08-27 2016-09-27 Emory University Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
UA100836C2 (ru) 2005-02-23 2013-02-11 Бавариан Нордик А/С Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
ES2281252B1 (es) 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
CN101020052A (zh) * 2006-02-16 2007-08-22 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的艾滋病疫苗
EP2040747A4 (de) * 2006-06-19 2010-08-25 Progenics Pharm Inc Lösliche stabilisierte trimere hiv-hüllproteine und ihre verwendung
CA2655929A1 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
DK2062023T4 (en) 2006-08-25 2017-02-20 The Government Of The Us Secretary Dept Of Health And Human Services INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS
US7939083B2 (en) 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
DK2488649T3 (da) 2009-10-16 2019-06-17 Us Health Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US9839684B2 (en) 2011-04-06 2017-12-12 Biovaxim Limited Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
CA2849652C (en) 2011-09-26 2017-11-21 Theravectys Use of non-subtype b gag proteins for lentiviral packaging
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015127108A1 (en) * 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
CN106999571B (zh) 2014-09-26 2020-10-02 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
DK3584252T3 (da) 2015-12-15 2021-11-15 Janssen Vaccines & Prevention Bv Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
JP2019526580A (ja) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
WO2002088353A2 (en) * 2001-04-27 2002-11-07 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Method for the stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US838122A (en) 1905-10-12 1906-12-11 American Steel Package Company Sheet-metal can.
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
AU570940B2 (en) 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
EP2388015A1 (de) * 2000-03-02 2011-11-23 Emory University DNA-Expressionsvektoren und Verwendungsverfahren
EP2363143A3 (de) * 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene
US9453239B2 (en) 2004-08-27 2016-09-27 Emory University Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
WO2002088353A2 (en) * 2001-04-27 2002-11-07 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Method for the stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CARROLL M W ET AL: "E. COLI BETA-GLUCURONIDASE (GUS) AS A MARKER FOR RECOMBINANT VACCINIA VIRUSES", BIOTECHNIQUES, INFORMA HEALTHCARE, US, vol. 19, no. 3, 1 September 1995 (1995-09-01), XP001074085, ISSN: 0736-6205 *
DATABASE EMBL [online] 4 September 2002 (2002-09-04), "HIV-1 isolate 00KE_KER2008 from Kenya, partial genome.", XP002484826, retrieved from EBI accession no. EMBL:AF457052 Database accession no. AF457052 *
DATABASE EMBL [online] 4 September 2002 (2002-09-04), "HIV-1 isolate 00KE_KNH1144 from Kenya, partial genome.", XP002484827, retrieved from EBI accession no. EMBL:AF457066 Database accession no. AF457066 *
DATABASE EMBL [online] 4 September 2002 (2002-09-04), "HIV-1 isolate 00KE_KNH1207 from Kenya, partial genome.", XP002484828, retrieved from EBI accession no. EMBL:AF457068 Database accession no. AF457068 *
DOWLING WILLIAM E ET AL: "Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants.", AIDS (LONDON, ENGLAND) 6 SEP 2002, vol. 16, no. 13, 6 September 2002 (2002-09-06), pages 1809 - 1820, XP002484823, ISSN: 0269-9370 *
EARL P L ET AL: "Comparison of Vaccine Strategies Using Recombinant env-gag-pol MVA with or without an Oligomeric Env Protein Boost in the SHIV Rhesus Macaque Model", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 294, no. 2, 15 March 2002 (2002-03-15), pages 270 - 281, XP004467124, ISSN: 0042-6822 *
MEYER H ET AL: "MAPPING OF DELETIONS IN THE GENOME OF THE HIGHLY ATTENUATED VACCINIA VIRUS MVA AND THEIR INFUENCE ON VIRULENCE", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 72, 1 January 1991 (1991-01-01), pages 1031 - 1038, XP000952390, ISSN: 0022-1317 *
SUTTER G ET AL: "NONREPLICATING VACCINIA VECTOR EFFICIENTLY EXPRESSES RECOMBINANT GENES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 89, 1 November 1992 (1992-11-01), pages 10847 - 10851, XP001036843, ISSN: 0027-8424, DOI: 10.1073/PNAS.89.22.10847 *

Also Published As

Publication number Publication date
US20110159036A1 (en) 2011-06-30
AU2004226345A1 (en) 2004-10-14
EP2371380A1 (de) 2011-10-05
WO2004087201A3 (en) 2005-03-31
EP1610816A2 (de) 2006-01-04
WO2004087201A2 (en) 2004-10-14
US20060134133A1 (en) 2006-06-22
EP2359851A2 (de) 2011-08-24
EP2363143A2 (de) 2011-09-07
EP2359851A3 (de) 2011-08-31
EP1610816B1 (de) 2013-01-02
AU2004226345B2 (en) 2011-12-22
CA2520637A1 (en) 2004-10-14
US7303754B2 (en) 2007-12-04

Similar Documents

Publication Publication Date Title
EP2363143A3 (de) MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene
WO2002072754A3 (en) Mva expressing modified hiv envelope, gag, and pol genes
EP2319860A3 (de) Rekombinante MVA-Viren, Clade-A/G-, Clade-B- und Clade-C-modifizierte HIV env, gag- und pol-Gene exprimierend
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
ZA200602858B (en) HIV vaccines based on Env of multiple clades of HIF
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
EP2280073A3 (de) Impfstoff zur Vorbeugung oder Behandlung einer HIV-Infektion
EP0887427A3 (de) Amplifizierung und Detektion von HIV-1 und/oder HIV-2
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
WO2007022371A3 (en) Chemokine receptor binding compounds
HK1051317A1 (zh) 新用途
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
WO2005059107A3 (en) Chemokine receptor binding compounds
WO2002065834A8 (en) Novel formulations of carvedilol
WO2002087614A3 (en) Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2006138259A3 (en) Chemokine receptor binding compounds
EP0816487A4 (de) Zelle, die rekombinanten hiv produziert
WO2000061067A3 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
WO2002042482A3 (en) Functional lentiviral vector from an mlv-based backbone
JP2002508338A5 (de)
WO2001057245A3 (en) Hiv-1 resistance assay
EP2128256A3 (de) Molekulare Klone mit mutierten HIV-GAG/POL-, SIV-GAG- und SIV-ENV-Genen
HK1109407A (en) Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
WO2007002172A3 (en) Hiv-1 protease inhibitors
NO20081230L (no) Inhibitorer av enzymet HIV integrase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1610816

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/285 20060101ALI20120111BHEP

Ipc: A61K 39/21 20060101ALI20120111BHEP

Ipc: A61K 39/275 20060101ALI20120111BHEP

Ipc: A61K 39/12 20060101AFI20120111BHEP

17P Request for examination filed

Effective date: 20120618

17Q First examination report despatched

Effective date: 20130731

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131001